Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2608

Sigma-Aldrich

CSRM617 Hydrochloride

≥98% (HPLC)

Synonym(s):

(2,3,4-Trihydroxyphenyl-methylidene)-hydrazino-2-amino-3-hydroxy-1-propanone hydrochloride, 2-Amino-3-hydroxy-N′-(2,3,4-trihydroxybenzylidene)propanehydrazide hydrochloride, 2-[(2,3,4-trihydroxyphenyl)methylene] serinehydrazide hydrochloride (1:1)

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H13N3O5 · HCl
CAS Number:
1353749-74-2
Molecular Weight:
291.69
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

OC1=C(C=CC(O)=C1O)C=NNC(C(CO)N)=O.Cl

InChI key

YBUPSOQAGSOATG-UHFFFAOYSA-N

Biochem/physiol Actions

CSRM617 is an ONECUT2 (OC2) inhibitor that directly targets OC2 HOX domain (KD = 7.43 μM) and disrupts OC2 target genes promoter binding. CSRM617 blocks OC2-dependent prostate cancer growth in cultures (IC50 = 4-50 μM; 48 h) via apoptosis induction (fold of untreated annexin V population = 2.3/10 μM, 3.5/20 μM; 22Rv1) and exhibits in vivo efficacy against metastases as well as the growth of established 22Rv1 tumor in mice in vivo (50 mg/kg/day ip.).
HOX domain-targeting ONECUT2 (OC2) inhibitor against OC2-dependent prostate cancer growth in vitro and in vivo.

Signal Word

Warning

Hazard Statements

H317,H319,H341,H410

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1 - Eye Irrit. 2 - Muta. 2 - Skin Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mirja Rotinen et al.
Nature medicine, 24(12), 1887-1898 (2018-11-28)
Treatment of prostate cancer (PC) by androgen suppression promotes the emergence of aggressive variants that are androgen receptor (AR) independent. Here we identify the transcription factor ONECUT2 (OC2) as a master regulator of AR networks in metastatic castration-resistant prostate cancer

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service